ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DYSPORT
Aesthetic medicine
Muscle spasms
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

DYSPORT Rx

Generic Name and Formulations:
AbobotulinumtoxinA 300 Units, 500 Units; per vial; lyophilized pwd for IM inj after reconstitution; contains human albumin, lactose. May contain cow's milk proteins (trace amounts).

Company:
Ipsen Biopharmaceuticals, Inc.

Therapeutic Use:

Indications for DYSPORT:

Temporary improvement in the appearance of moderate-to-severe glabellar lines associated with procerus and corrugator muscle activity in adults <65yrs.

Adult:

Should be administered and managed by experienced physicians. Give by IM inj a total of 50 Units divided in 5 equal aliquots of 10 Units each to affected muscles to achieve clinical effect. May repeat treatment no more than every 3 months.

Children:

<18yrs: not recommended.

Contraindications:

Cow's milk protein allergy. Infection at proposed inj site.

Warnings/Precautions:

Risk of distant spread of toxin effect esp. in children. Not interchangeable with other botulinum toxin products. Pre-existing dysphagia or breathing difficulties. Compromised respiratory status. Neuromuscular disorders (eg, myasthenia gravis, ALS, Lambert-Eaton syndrome); monitor closely. Contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Elderly. Pregnancy. Nursing mothers.

Interactions:

May be potentiated by aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds). May potentiate anticholinergic effects with concomitant anticholinergic drugs. Concomitant other botulinum toxin products or muscle relaxants may potentiate neuromuscular weakness.

Pharmacological Class:

Neuromuscular blocker.

Adverse Reactions:

Muscular weakness, dysphagia, dry mouth, inj site pain/discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, eye disorders, upper RTI, UTI, nasopharyngitis, dizziness, fall, depression.

Generic Availability:

NO

How Supplied:

Single-use vial (300 Units)—1; (500 Units)—1, 2

Indications for DYSPORT:

Treatment of spasticity in patients ≥18yrs. Cervical dystonia in patients ≥18yrs. Lower limb spasticity in children ≥2yrs.

Adult:

Should be administered and managed by experienced physicians. Individualize; see full labeling. Spasticity: usual range: 500–1000 Units (upper limb) or 1000–1500 Units (lower limb) divided among selected muscles per treatment session; max 1mL/site. Total max 1500 Units for upper and lower limb combined. May repeat treatment after effect of the previous injection diminishes, but no sooner than 12 weeks. Cervical dystonia: initially 500 Units divided among affected muscles. May adjust dose in 250 Unit steps based on response; max 1000 Units/dose. May repeat treatment no sooner than 12 weeks.

Children:

Should be administered and managed by experienced physicians. Upper limb spasticity, cervical dystonia: <18yrs: not established. Lower limb spasticity: <2yrs: not established. Individualize; see full labeling. ≥2yrs: usually 10–15 Units/kg total for unilateral inj or 20–30 Units/kg total for bilateral inj divided between the affected muscles per treatment session; max 0.5mL/site. Total dose per treatment session: max 15 Units/kg for unilateral inj, 30 Units/kg for bilateral inj, or 1000 Units, whichever is lower. May repeat treatment after effect of the previous injection diminishes, but no sooner than 12 weeks.

Contraindications:

Cow's milk protein allergy. Infection at proposed inj site.

Warnings/Precautions:

Risk of distant spread of toxin effect esp. in children. Not interchangeable with other botulinum toxin products. Pre-existing dysphagia or breathing difficulties. Compromised respiratory status. Neuromuscular disorders (eg, myasthenia gravis, ALS, Lambert-Eaton syndrome); monitor closely. Contains human albumin; monitor for possible viral disease and Creutzfeldt-Jakob disease transmission. Elderly. Pregnancy. Nursing mothers.

Interactions:

May be potentiated by aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds). May potentiate anticholinergic effects with concomitant anticholinergic drugs. Concomitant other botulinum toxin products or muscle relaxants may potentiate neuromuscular weakness.

Pharmacological Class:

Neuromuscular blocker.

Adverse Reactions:

Muscular weakness, dysphagia, dry mouth, inj site pain/discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, eye disorders, upper RTI, UTI, nasopharyngitis, dizziness, fall, depression.

Generic Availability:

NO

How Supplied:

Single-use vial (300 Units)—1; (500 Units)—1, 2

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs